Large Pharmaceuticals
Market Cap
₹1,19,202 ₹1.19 L Cr.
P/E
28.52
PEG
2.91
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The bull thesis activates if Saroglitazar gains US approval ahead of schedule with broad label potential, causing specialty revenue to rapidly re-rate the multiple from generic to innovation-led pharma.

The bear case crystallizes if the Saroglitazar NDA is rejected or delayed, removing the critical high-margin recovery driver and compressing margins through FY29 as US generics erosion accelerates.

The base case depends on International Markets compounding at 25% for five years to offset North America's declining share, with any deceleration posing the single largest risk to the revenue trajectory.

Compare companies on business attributes

Every company is scored 0 to 10 on 61 measured business attributes. We default to the attributes that actually separate your peer set. Add companies or pick your own at any time.

As of 17 Nov 2026
Zydus Lifesciences
Business quality
Strategic-anchor / hyperscaler customer quality 7.0 7.0 5.0 2.0 10.0
Growth & capacity
Growth momentum 8.5 4.0 3.0 7.0 6.0
Growth mix: volume vs price +3.0 +2.0 +2.0 -1.0 +4.0
Financial strength
Earnings consistency 10.0 3.0 5.0 5.0 5.0
Working-capital discipline 10.0 3.0 10.0 10.0 10.0
Receivables / collection risk 7.5 10.0 7.5 5.1 7.5
Capabilities
R&D / innovation intensity 10.0 10.0 8.0 6.0 8.0
Market position & risk
Policy / formalisation tailwind 10.0 10.0 10.0 0.0 10.0
B2B vs B2C orientation 7.0 5.0 5.0 2.0 9.0
Customer concentration quantum 1.0 4.0 5.0 0.0 5.0
Urban / housing / discretionary exposure 2.0 0.0 0.0 5.0 0.0
Rural demand exposure 2.0 0.0 3.0 4.0 0.0
Inputs & currency
Foreign revenue / export orientation 6.0 8.0 5.0 1.0 9.0
Foreign-currency cost exposure 4.0 5.0 5.0 1.0 6.0
China sourcing dependency NA 3.0 3.0 3.0 7.0
Governance & capital allocation
Promoter holding / control level 10.0 3.0 3.0 10.0 5.0
Intangibles intensity 10.0 7.0 5.0 10.0 3.0
Dilution dependence 0.0 0.0 0.0 5.0 0.0
Promoter pledge risk 0.0 0.0 0.0 0.0 5.0
Conglomerate / group exposure 3.0 0.0 0.0 0.0 5.0

Radar View

Insights

  • Zydus Lifesciences

    Makes medicines and wellness brands for India and the US, built on novel drug and biosimilar research; the bet is that specialty launches offset generic erosion.

  • Dr. Reddy's Labs.

    Sells generic, branded, and consumer medicines globally with 80 pending US R&D filings; the bet is that biosimilar and peptide launches offset fading US generic profits.

  • Cipla

    Makes drugs and inhalers for global patients, with over 60% of India prescriptions in chronic refills; the bet is that new US inhaler launches rebuild margins.

  • Mankind Pharma

    Makes Indian prescription drugs and consumer brands sold via 17,600+ stockists, no customer over 10%; the bet is that chronic drugs and specialty biologics lift margins.

  • Aurobindo Pharma

    Makes generic medicines and active ingredients for US and European buyers and partner MSD; the bet is that biosimilars, MSD biologics, and underutilised plants scale up.

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material